Takashi Kei Kishimoto insider trades: Selecta Biosciences (SELB) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Takashi reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 5, 2023 | SELB | ↓ Sell | 9,784 | $1.13 | $11K | Direct | Jan 6, 2023 (1d) |
| Jan 5, 2022 | SELB | ↓ Sell | 3,416 | $3.09 | $11K | Direct | Jan 7, 2022 (2d) |
| Dec 10, 2021 | SELB | ↓ Sell | 4,370 | $2.99 | $13K | Direct | Dec 14, 2021 (4d) |
| Oct 13, 2021 | SELB | ↓ Sell | 3,892 | $4.39 | $17K | Direct | Oct 15, 2021 (2d) |
| Dec 28, 2016 | SELB | ↓ Sell | 10,000 | $17.55 | $176K | Direct | Dec 30, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Takashi Kei Kishimoto's insider trades
Takashi Kei Kishimoto is Chief Scientific Officer at Selecta Biosciences (SELB). Since Dec 28, 2016, Takashi has reported no open-market purchases and 5 sales worth $227K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), option exercises (4 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SELB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.